- Conditions
- Atopic Dermatitis
- Interventions
- GIA632, Placebo
- Drug · Other
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 3
- States / cities
- Fremont, California • Rockville, Maryland • Hoboken, New Jersey
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2089–2112
of 21,226
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Systemic Lupus Erythematosus, COVID-19
- Interventions
- LEAP Education + Navigation, LEAP Education
- Behavioral
- Lead sponsor
- Tulane University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 274 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- New Orleans, Louisiana
- Conditions
- Chronic Myeloproliferative Disorders, Diamond-blackfan Anemia, Fanconi Anemia, Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
- Interventions
- anti-thymocyte globulin, busulfan, cyclophosphamide, cyclosporine, filgrastim, melphalan, methylprednisolone, mycophenolate mofetil, radiation therapy, umbilical cord blood transplantation
- Drug · Procedure
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- Up to 45 Years
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2007
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Type 1 Diabetes, Type 2 Diabetes
- Interventions
- Bionic Pancreas, Usual Care
- Device · Other
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Congestive Heart Failure, Asthma, Chronic Obstructive Pulmonary Disease, Cystic Fibrosis
- Interventions
- Respiratory Sensor measurements
- Device
- Lead sponsor
- Institute of Bioengineering and Bioimaging (IBB)
- Government
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Depression, Substance-Related Disorders, HIV Infections
- Interventions
- Antidepressant Medication
- Drug
- Lead sponsor
- Butler Hospital
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 265 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2004
- U.S. locations
- 1
- States / cities
- Providence, Rhode Island
- Conditions
- Chronic Spontaneous Urticaria (CSU), Chronic Idiopathic Urticaria
- Interventions
- THB335 Lower Dose, THB335 Higher Dose, Placebo
- Drug
- Lead sponsor
- Calixis Inc.
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 81 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 15
- States / cities
- Pasadena, California • Ventura, California • Walnut Creek, California + 12 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- Rituximab
- Biological
- Lead sponsor
- Gaylis, Norman B., M.D.
- Individual
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 6
- States / cities
- Fort Lauderdale, Florida • Hollywood, Florida • Miami, Florida + 2 more
- Conditions
- Plasma Cell Myeloma
- Interventions
- Autologous Hematopoietic Stem Cell Transplantation, Daratumumab, Lenalidomide
- Procedure · Biological · Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Graft vs Host Disease
- Interventions
- Infliximab
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- Up to 18 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Ends 2006
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Atopic Dermatitis, Pruritus, Sleep Disturbance
- Interventions
- Not listed
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 12 Years to 75 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Lymphoma
- Interventions
- Non-Interventional
- Other
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 95 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 2
- States / cities
- Lawrenceville, New Jersey • Milwaukee, Wisconsin
- Conditions
- Multiple Sclerosis
- Interventions
- Not listed
- Lead sponsor
- EMD Serono
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 599 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 2
- States / cities
- Phoenix, Arizona • Las Vegas, Nevada
- Conditions
- HIV Infections
- Interventions
- Ritonavir, Nelfinavir mesylate, Levocarnitine, Adefovir dipivoxil, Saquinavir, Delavirdine mesylate
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 16 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 1999
- U.S. locations
- 45
- States / cities
- Birmingham, Alabama • Los Angeles, California • Menlo Park, California + 27 more
- Conditions
- Chronic Pain, Fibromyalgia, Osteoarthritis, Knee, Osteoarthritis, Hip, Osteoarthritis, Ankylosing Spondylitis, Rheumatoid Arthritis, Chronic Low-back Pain, Chronic Shoulder Pain
- Interventions
- No intervention, observational only.
- Other
- Lead sponsor
- Illinois Institute of Technology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- B-cell Acute Lymphoblastic Leukemia
- Interventions
- Blinatumomab
- Drug
- Lead sponsor
- Dorothy Sipkins, MD, PhD
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 3
- States / cities
- Tampa, Florida • Durham, North Carolina • Winston-Salem, North Carolina
- Conditions
- Acute Lymphoblastic Leukemia
- Interventions
- 6-Mercaptopurine
- Drug
- Lead sponsor
- Roxane Laboratories
- Industry
- Eligibility
- 18 Years to 45 Years · Male only
- Enrollment
- 54 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2002
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona
- Conditions
- Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma, Recurrent Follicular Lymphoma, Refractory Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma
- Interventions
- Ibrutinib, Radiation Therapy, TLR9 Agonist SD-101
- Drug · Radiation
- Lead sponsor
- Robert Lowsky
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Mantle Cell Lymphoma
- Interventions
- Leuprolide acetate depot (LAD) 11.25 mg 3 Month, Matched placebo
- Drug
- Lead sponsor
- Abbott
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2006
- U.S. locations
- 4
- States / cities
- St Louis, Missouri • New York, New York • Durham, North Carolina + 1 more
- Conditions
- Cryptosporidiosis, HIV Infections
- Interventions
- Spiramycin
- Drug
- Lead sponsor
- Rhone-Poulenc Rorer
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- Horsham, Pennsylvania
- Conditions
- COVID-19
- Interventions
- Not listed
- Lead sponsor
- ObvioHealth
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 804 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Orlando, Florida
- Conditions
- Lymphoproliferative Disorder
- Interventions
- rituximab, cyclophosphamide, methylprednisolone, prednisone
- Biological · Drug
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 30 Years
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2013
- U.S. locations
- 66
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 58 more
- Conditions
- B-cell Non-Hodgkin Lymphoma
- Interventions
- Mosunetuzumab, Polatuzumab Vedotin, Rituxumab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Tocilizumab
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 117 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • La Jolla, California + 12 more
- Conditions
- Hematologic Malignancies
- Interventions
- Haplo HCT ≥55 years old, GVHD Prophylaxis, Haplo HCT ≥55 and < 65 years old, Haplo HCT ≥65 and ≤75 years old
- Biological · Drug
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- Up to 75 Years
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota